in only 2 days, the INTEGRATE and  ERN ReCONNET surveys will be closed. Yet, we miss feedback from several countries, and only have 1 or 2 answers from others. It would really help our understanding of lupus and the interactions with Doctors if we had more answers from more locations. please help us gather that extra feedback by answering the surveys if you have not done yet, and by forwarding to your lupus friends… The information you will provide will be analysed by a multi-functional team, in which LUPUS EUROPE is represented, to trigger action, influence projects and/or guide decisions.

INTEGRATE SURVEY:
The survey is part of the INTEGRATE project (www.integrate-sle.eu), a project funded by the European Commission involving the University of Pisa (Italy), the University of Dusseldorf (Germany) and the Sant’ Anna School of Advanced Studies (Italy).
The aim of the project is to map the needs and expectations of patients with SLE and the rheumatologists involved in their care and management in order to design strategies integrating both points of view, with the final goal to improve management and self-management of the disease.
As SLE patient you have been invited to participate to the survey, through the LUPUS EUROPE association or your clinician, to give voice to patients with SLE.

To complete the survey (in English, Italian  or German (revised)), please follow this link https://www.integrate-sle.eu 
Thank you in advance for providing your feedback by  15th February 2019!
Your participation and your time will be really appreciated and it will surely contribute to the success of the initiative.

 

If you have some timle left, also complete the ERN RECONNET Survey :
RECONNET is the European Reference Network on rare and complex connective tissue diseases. It brings together Healthcare Providers and patients to improve the quality of care, the activity of the physicians, and the empowerment of patients across Europe. The survey collects simple feedback on different aspects related to ethical, legal and privacy issue, and on cross-border healthcare. It is available in Dutch, English, French, Italian, German, Portuguese and Spanish:
Dutch : https://goo.gl/forms/jnhl45rosttSLXUt1
English: https://goo.gl/forms/eK4v5ziNGJqRkRsr2
French: https://goo.gl/forms/q6mkhu4cl3k5YKZq1
Italian: https://goo.gl/forms/ps9uzr4piTdperyK2
German: https://goo.gl/forms/TNZRBvCFFZ3tIHon1
Portuguese: https://goo.gl/forms/UMV0tvXUFBW0wp0T2
Spanish: https://goo.gl/forms/MHgBfBRjlLVMVZeJ3

Remember that these surveys have limited availability and time is of the essence, so thank you for your prompt feedback.

THANK YOU

LUPUS EUROPE’s Board

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons
3 days ago
LUPUS EUROPE

🚨 Call for patients🚨

🔊 INSPIRE SURVEY from the University of Cambridge.

This survey aims to improve the understanding of neurological symptoms in SLE and other rheumatic conditions.

Lupus is a very heterogeneous disease, which means that it affects people of different ethnic backgrounds and gender in different ways.

That is why, to get accurate research results, as many different groups as possible must be represented in the sample.

The INSPIRE survey was launched last year to get the patient experience on the assessment/monitoring of neurological symptoms, but they received very few responses from people from ethnic minorities.

That is why the research team led by Dr Chris Wincup has launched a new survey.

The new INSPIRE survey can be completed by lupus patients or their carers from around the world.

🟣 Please share as much as possible 🟣 in order to get a sample that includes a good proportion of all ethnic groups.

Thank you!

bit.ly/inspire_patients_short
... See MoreSee Less

Comment on Facebook

I did it a second time and no it went good till the end

The survey was demolished.

4 days ago
LUPUS EUROPE

Discoid lupus erythematosus (DLE) is the most common form of chronic cutaneous lupus erythematosus. It is characterised by persistent scaly plaques on the scalp, face, and ears, which can progress to scarring, atrophy, depigmentation, and permanent hair loss in affected hair-bearing areas (Source: DermNet).

This study, published by Prof Marca Mosca et al., describes 2 cases of severe and refractory DLE successfully treated with anifrolumab, a human monoclonal antibody.

Although anifrolumab has been recently approved for the treatment of SLE, data from randomized clinical trials have shown a significant difference in cutaneous response rate in patients treated with anifrolumab from those in the placebo group.

While the effectiveness of this treatment in real life and in different types of skin lesions has yet to be determined, it could represent a new valid opportunity for treating DLE.

jamanetwork.com/journals/jamadermatology/article-abstract/2798967
... See MoreSee Less

Discoid lupus erythematosus (DLE) is the most common form of chronic cutaneous lupus erythematosus. It is characterised by persistent scaly plaques on the scalp, face, and ears, which can progress to scarring, atrophy, depigmentation, and permanent hair loss in affected hair-bearing areas (Source: DermNet). 

This study, published by Prof Marca Mosca et al., describes 2 cases of severe and refractory DLE successfully treated with anifrolumab, a human monoclonal antibody. 

Although anifrolumab has been recently approved for the treatment of SLE, data from randomized clinical trials have shown a significant difference in cutaneous response rate in patients treated with anifrolumab from those in the placebo group. 

While the effectiveness of this treatment in real life and in different types of skin lesions has yet to be determined, it could represent a new valid opportunity for treating DLE.

https://jamanetwork.com/journals/jamadermatology/article-abstract/2798967Image attachmentImage attachment
5 days ago
LUPUS EUROPE

We know some of you missed the great seminar recently delivered by Prof. Laurent Arnaud.

Well, no worries!

You have the chance to see it again, thanks to the European Federation of Internal Medicine (EFIM).

"Challenges in 2023 for Systemic Lupus Erythematosus".

Next 29th of March at 18:00 CET (i.e. Paris time).

Register for free here!

us02web.zoom.us/webinar/register/WN_O5yMwjfgTS29pMKvOZfgZw
... See MoreSee Less

We know some of you missed the great seminar recently delivered by Prof. Laurent Arnaud. 

Well, no worries! 

You have the chance to see it again, thanks to the European Federation of Internal Medicine (EFIM). 

Challenges in 2023 for Systemic Lupus Erythematosus.

Next 29th of March at 18:00 CET (i.e. Paris time).

Register for free here! 

https://us02web.zoom.us/webinar/register/WN_O5yMwjfgTS29pMKvOZfgZwImage attachment
6 days ago
LUPUS EUROPE

Did you miss this ERN RECONNET webinar with Lou Kawka and Prof Laurent Arnaud about #fatigue in #SLE?

Now you have the chance to watch it!!! 😃🙌

www.youtube.com/watch?v=7jc7SiP5BsA
... See MoreSee Less

Did you miss this ERN RECONNET webinar with Lou Kawka and Prof Laurent Arnaud about #fatigue in #SLE? 

Now you have the chance to watch it!!! 😃🙌

https://www.youtube.com/watch?v=7jc7SiP5BsA
LUPUS EUROPE Uniting people with Lupus throughout Europe
Send